IPO Timeline
Broker Results (T-2)
2023-09-01
Some brokers release in afternoon
Grey Market (T-1)
2023-09-04
Afternoon
HKEX Allotment (T-1)
2023-09-04
Evening
Registrar Allotment (T-1)
2023-09-04
Evening
Listing Day (T)
2023-09-05
First day of trading
Company Overview
| Stock Name | 宜明昂科－Ｂ |
|---|---|
| Stock Code | 01541 |
| Company Full Name | 宜明昂科－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家以科研為導向的生物技術公司，致力于開發腫瘤免疫療法。 |
| Listing Date | 2023-09-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區中國（上海）自由貿易試驗區張衡路1000弄15號樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.immuneonco.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 72.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 31,895,280 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,720 |
| 2 lots | 400 | HK$ 7,440 |
| 3 lots | 600 | HK$ 11,160 |
| 4 lots | 800 | HK$ 14,880 |
| 5 lots | 1,000 | HK$ 18,600 |
| 6 lots | 1,200 | HK$ 22,320 |
| 7 lots | 1,400 | HK$ 26,040 |
| 8 lots | 1,600 | HK$ 29,760 |
| 9 lots | 1,800 | HK$ 33,480 |
| 10 lots | 2,000 | HK$ 37,200 |
| 15 lots | 3,000 | HK$ 55,800 |
| 20 lots | 4,000 | HK$ 74,400 |
| 25 lots | 5,000 | HK$ 93,000 |
| 30 lots | 6,000 | HK$ 111,600 |
| 35 lots | 7,000 | HK$ 130,200 |
| 40 lots | 8,000 | HK$ 148,800 |
| 45 lots | 9,000 | HK$ 167,400 |
| 50 lots | 10,000 | HK$ 186,000 |
| 75 lots | 15,000 | HK$ 279,000 |
| 100 lots | 20,000 | HK$ 372,000 |
| 125 lots | 25,000 | HK$ 465,000 |
| 150 lots | 30,000 | HK$ 558,000 |
| 175 lots | 35,000 | HK$ 651,000 |
| 200 lots | 40,000 | HK$ 744,000 |
| 225 lots | 45,000 | HK$ 837,000 |
| 250 lots | 50,000 | HK$ 930,000 |
| 300 lots | 60,000 | HK$ 1,116,000 |
| 400 lots | 80,000 | HK$ 1,488,000 |
| 500 lots | 100,000 | HK$ 1,860,000 |
| 750 lots | 150,000 | HK$ 2,790,000 |
| 1,000 lots | 200,000 | HK$ 3,720,000 |
| 1,250 lots | 250,000 | HK$ 4,650,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 5,580,000 |
| 1,750 lots | 350,000 | HK$ 6,510,000 |
| 4,287 lots | 857,400 | HK$ 15,947,640 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 19.52 |
|---|---|
| First Day Open | HK$ 21.2 |
| First Day Change | 4.95% |
| First Day Volume | 894500.0 |
| First Day Turnover | 18659600.0 |
Use of Proceeds
| Use of Proceeds | 1、約40.0%，或93.8百萬港元，將用于我們核心產品IMM01（SIRPα-Fc融合蛋白）正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市； 2、約28.0%，或65.7百萬港元，將用于我們核心產品IMM0306（CD47×CD20）、IMM2902（CD47×HER2）及IMM2520（CD47×PD-L1）正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市； 3、約10.0%，或23.5百萬港元，將用于IMM47（CD24單克隆抗體）計劃開展的臨床試驗； 4、約5.0%，或11.7百萬港元，將用于IMM2510(VEGF×PD-L1)及IMM27M（CTLA4ADCC增強型單克隆抗體）正在進行的臨床試驗； 5、約7.0%，或16.4百萬港元，將用于建設我們于上海張江科學城的新生產設施； 6、約5.0%，或11.7百萬港元，將用于我們多個臨床前及發現階段資產的持續臨床前研發以及CMC以支持臨床試驗； 7、約5.0%，或11.7百萬港元，將用于營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (8)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
复星国际证券有限公司 CE AAF432
招银国际融资有限公司 CE AVM940
中银国际亚洲有限公司 CE AET863
工银国际证券有限公司 CE ARO299
东吴证券国际经纪有限公司 CE AYA587
富途证券国际（香港）有限公司 CE AZT137
Joint Lead Managers (8)
摩根士丹利亚洲有限公司 CE AAD291
中国国际金融香港证券有限公司 CE AEN894
复星国际证券有限公司 CE AAF432
招银国际融资有限公司 CE AVM940
中银国际亚洲有限公司 CE AET863
工银国际证券有限公司 CE ARO299
东吴证券国际经纪有限公司 CE AYA587
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 156,626,880 HKD | — | 49.11% | — | 6 months | 2024-03-05 |
| 2 | WuXi Biologics Healthcare Venture | 39,093,480 HKD | — | 12.26% | — | 6 months | 2024-03-05 |
| 3 | 昆翎医药发展有限公司 | 15,504,960 HKD | — | 4.86% | — | 6 months | 2024-03-05 |
| 4 | 荣昌生物香港有限公司 | 20,999,400 HKD | — | 6.58% | — | 6 months | 2024-03-05 |
Directors & Management
| Chairman | 田文志 |
|---|---|
| Company Secretary | 關梅,李健威 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 田文志(18.80%);禮來亞洲基金(11.70%);上海張科領弋升帆創業投資中心(有限合伙)(11.34%);北京龍磐健康醫療投資中心(有限合伙)(5.16%) |
|---|
Subscription Tiers
IPO Timeline
